Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 9/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 9/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 9/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9430962 | 0.79 | CHRM2 (0.66) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9187577 | 0.79 | CHRM2 (0.64) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9459030 | 0.78 | CHRM1 (0.64) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8775355 | 0.77 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9183644 | 0.76 | CHRM1 (0.61) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9430802 | 0.76 | CHRM1 (0.61) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8775322 | 0.75 | CHRM1 (0.59) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8621343 | 0.74 | CHRM1 (0.59) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9431134 | 0.73 | CHRM1 (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9430968 | 0.72 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5346906-A | Enhancement of cholinergic transmitters in treatment of neurological and mental disorders such as Alzheimer's | MERCK SHARPE & DOHME LTD. (GB) | 1994-09-13 | — | — | US | claimed |
| EP-0492902-A1 | Substituted pyridine derivatives for use in the treatment of glaucoma | MERCK SHARP & DOHME LTD. (GB) | 1992-07-01 | — | — | EP | claimed |
| EP-0412798-A2 | Substituted pyridines, their preparation, formulations and use in dementia | MERCK SHARP & DOHME LTD. (GB) | 1991-02-13 | — | — | EP | claimed |
| JP-3135978-A | — | — | None | — | — | JP | disclosed |
| JP-5140158-A | — | — | None | — | — | JP | disclosed |
| US-5346906-A | Enhancement of cholinergic transmitters in treatment of neurological and mental disorders such as Alzheimer's | MERCK SHARPE & DOHME LTD. (GB) | 1994-09-13 | — | — | US | disclosed |
| JP-H05140158-A | SUBSTITUTED PYRIDINE DERIVATIVE USEFUL IN TREATMENT OF GLAUCOMA | MERCK SHARP & DOHME LTD | 1993-06-08 | — | — | JP | disclosed |
| EP-0492902-A1 | Substituted pyridine derivatives for use in the treatment of glaucoma | MERCK SHARP & DOHME LTD. (GB) | 1992-07-01 | — | — | EP | disclosed |
| EP-0492902-A1 | Substituted pyridine derivatives for use in the treatment of glaucoma | MERCK SHARP & DOHME LTD. (GB) | 1992-07-01 | — | — | EP | disclosed |
| JP-H03135978-A | SUBSTITUTED PYRIDINES, THEIR PRODUCTIONS, FORMULATION AND USE FOR DEMENTIA | MERCK SHARP & DOHME LTD | 1991-06-10 | — | — | JP | disclosed |
| EP-0412798-A2 | Substituted pyridines, their preparation, formulations and use in dementia | MERCK SHARP & DOHME LTD. (GB) | 1991-02-13 | — | — | EP | disclosed |